Medical Oncologist
Medicines
Do you need a PIK3CA test before alpelisib?
Alpelisib is only used when a breast cancer carries a PIK3CA mutation, so testing comes first. The test can use stored tumour tissue, a new biopsy or a blood sample. This page explains the options, what results mean, why a negative blood test is often checked with tissue, and how the result guides other treatment choices.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- Do you need a PIK3CA test before alpelisib?
- The ways PIK3CA can be tested
- What different results usually mean
- The vocabulary, in plain language
- The limits of testing
- Is a PIK3CA mutation inherited?
- Getting the test done
- Other ways the result can be useful
- What people assume about PIK3CA testing
- Common questions about PIK3CA testing
The short answer
Do you need a PIK3CA test before alpelisib?
Yes. Alpelisib is only used for breast cancers that carry a mutation in the PIK3CA gene, so a test is needed before it can be considered. This applies to hormone receptor positive, HER2-negative advanced or metastatic breast cancer, where around four in ten cancers have such a mutation. The test looks for specific changes in the gene. It can be done on tumour tissue, either stored from your original biopsy or surgery or taken from a newer biopsy, or on a blood sample that picks up tiny fragments of tumour DNA circulating in the blood. This blood test is often called a liquid biopsy. PIK3CA mutations usually arise early in a cancer's life and tend to stay, so older tissue is often suitable. A blood test is quicker and avoids a biopsy, but it can miss a mutation if little tumour DNA is in the blood. For that reason, if a blood test finds no mutation, a tissue test is usually advised before concluding that none is present. Many laboratories now use broader gene panels that look for PIK3CA alongside other useful changes, such as ESR1, AKT1, PTEN and BRCA, which can guide other treatment choices. Testing is usually done when metastatic disease is diagnosed or when first treatment stops working, so results are ready when a decision is needed.
No mutation, no alpelisib
Without a PIK3CA mutation, alpelisib is not expected to help.
Tissue or blood can be used
A negative blood result is usually checked with tissue.
Plan testing early
Results take time, so testing before they are needed avoids delays.
This page gives general information only. Ask your oncologist which test suits you.Testing options
The ways PIK3CA can be tested
Each approach has strengths and limits.
Stored tissue
Tissue kept from an earlier biopsy or operation can often be tested without another procedure.
Very old or small samples may not work.New biopsy
A fresh sample from a metastasis also confirms receptor status, which can change over time.
Blood test
Looks for tumour DNA in the blood. It is quick and simple, but it can miss mutations.
Gene panel
Tests many genes at once on tissue or blood.
May also find
- ESR1 mutations
- AKT1 or PTEN changes
- BRCA mutations
Understanding results
What different results usually mean
Result
What usually happens next
PIK3CA mutation detected
Alpelisib or another PI3K-pathway medicine may be considered
Not detected on tissue
Alpelisib is not used, and other options are discussed
Not detected on blood
A tissue test is usually advised before ruling it out
Test failed
A repeat on another sample or a blood test may be arranged
Other mutation found
It may point to a different targeted treatment
Words you will hear
The vocabulary, in plain language
- Mutation
- A change in a gene. In a tumour, it is usually acquired, not inherited.
- Liquid biopsy
- A blood test that looks for tumour DNA in the bloodstream.
- Circulating tumour DNA
- Small pieces of DNA released into the blood by cancer cells.
- Next-generation sequencing
- A laboratory method that reads many genes at the same time.
- Somatic mutation
- A change found in the cancer only, which cannot be passed to children.
- Archival tissue
- Tumour tissue stored in a laboratory from an earlier procedure.
Being straight with you
The limits of testing
PIK3CA testing is reliable in good laboratories, but no test is perfect.
False negatives happen
Blood tests in particular can miss a mutation when tumour DNA levels are low.
A positive result does not promise benefit
Having the mutation makes alpelisib an option, but not everyone with it responds.
Turnaround times vary
Results may take a week or more, and sending samples to another laboratory can add time.
What this page cannot tell you
It cannot interpret your own report. Your oncologist will explain what your result means.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Family worries
Is a PIK3CA mutation inherited?
Many people worry that a mutation found in their cancer might affect their children. For PIK3CA, this is very unlikely.
It develops in the cancer
PIK3CA mutations in breast cancer arise in the tumour cells during a person's life. They are not present in the rest of the body.
It does not affect family risk
Your children and relatives do not need testing because of this result.
Different from BRCA
If a gene panel suggests a BRCA mutation, that is a separate matter. It may be inherited, and genetic counselling can help your family.
Practical steps
Getting the test done
A little organisation helps avoid delays when your oncologist needs the result.
Locate your old samples
Tissue blocks are usually stored by the pathology laboratory that first examined them. Keep your earlier biopsy and surgery reports handy so they can be traced.
Ask which laboratory will test
Many accredited laboratories in India offer PIK3CA testing on tissue or blood. Your team will choose one they trust.
Ask about the scope
Find out whether the test looks only at PIK3CA or at a wider panel of genes.
Check insurance cover
Some policies cover gene tests when they guide treatment. Ask before the sample is sent.
Beyond alpelisib
Other ways the result can be useful
A PIK3CA result is not only about alpelisib. Newer medicines act on the same pathway.
Inavolisib
Used in some countries with palbociclib and fulvestrant for PIK3CA-mutated cancers that come back soon after hormone therapy.
Capivasertib
Used with fulvestrant for cancers with changes in PIK3CA, AKT1 or PTEN.
Clinical trials
Knowing your mutation status can make you eligible for studies of newer targeted medicines.
Commonly believed
What people assume about PIK3CA testing
A new biopsy is always needed.
Stored tissue or a blood sample is often enough.
A negative blood test settles it.
Blood tests can miss mutations, so tissue is usually checked too.
A PIK3CA mutation means my children are at risk.
It develops in the tumour and is not passed on.
Having a mutation means a worse outlook.
It mainly guides treatment choice. Your overall outlook depends on many factors.
Questions we are asked
Common questions about PIK3CA testing
When should the test be done?
Many oncologists test when metastatic disease is first diagnosed, or at the latest when the first treatment stops working. Testing early means the result is ready when a decision is needed, rather than delaying the next treatment while waiting for a report.
How long do results take?
It varies by laboratory and by the type of test. Blood tests are often quicker. Tracing and sending stored tissue can add several days. Ask your team roughly when to expect the report and how it will be shared with you.
Can I use my biopsy from several years ago?
Often yes, because PIK3CA mutations usually appear early and remain. The sample must contain enough tumour and be in good condition. If it is too small or too old to give a reliable result, a blood test or a new biopsy may be suggested.
Is the blood test as good as a tissue test?
When a blood test finds a mutation, the result is generally reliable. When it finds none, a mutation may still be present but missed, so tissue testing is usually recommended. Blood testing is especially useful when a biopsy is difficult or tissue is not available.
Why test for ESR1 at the same time?
ESR1 mutations often develop during hormone treatment and can make some hormone tablets less effective. Finding one may open up newer oral hormone medicines. Because ESR1 changes appear over time, a recent blood test is usually best for detecting them.
Does the test need fasting or special preparation?
No fasting is needed for the gene test itself. A blood sample is taken in the usual way. If you are having a new biopsy, you will be given separate instructions, such as when to stop blood thinners, and your team will explain what to expect.
What if I have no PIK3CA mutation?
Alpelisib is not used, but there are other options. These may include everolimus with exemestane, other hormone treatments, antibody-drug conjugates, chemotherapy, targeted medicines for other mutations, or clinical trials. Your oncologist will explain what suits you.
Will I need to repeat the test later?
A PIK3CA mutation found once usually remains, so repeating it is not always necessary. However, your oncologist may request later blood tests to look for newer changes, such as ESR1 mutations, that develop as treatment goes on.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- National Cancer Institute — Biomarker testing for cancer treatment
- US Food and Drug Administration — FDA approves alpelisib for metastatic breast cancer
- Cancer Research UK — Alpelisib (Piqray)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.